<DOC>
	<DOCNO>NCT02409199</DOCNO>
	<brief_summary>This multicenter , randomize study evaluate efficacy safety apatinib compare docetaxel treatment patient advance gastric cancer . At start trial , patient randomize one treatment arm : Arm A : apatinib 850mg qd every 3 week ; Arm B : docetaxel 60mg/m2 every 3 week . Tumor assessment do every 8 week accord RECIST 1.1 . The primary endpoint progression free survival ( PFS ) .</brief_summary>
	<brief_title>A Study Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Adult patient , age ≥18 year ; Histologically confirm advanced metastatic adenocarcinoma gastric cancer ( AGC ) , include adenocarcinoma gastroesophageal junction ; At least one measurable evaluable disease base response evaluation criterion solid tumor ( RECIST v1.1 ) ; Patients must receive one prior chemotherapy regimen AGC ; Firstline therapy must include combination least platinumbased treatment give concurrently , must experience disease progression firstline therapy disease ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Life expectancy 3 month ; Duration last therapy 6 week nitroso mitomycin , More 4 week cytotoxic agent , operation radiotherapy ; Adequate hepatic , renal , heart , hematologic function ( hemoglobin≥ 90g/L , platelet ≥ 80 × 109/L , neutrophil ≥1.5 × 109/L , serum creatinine≤ 1.5mg/dl , total bilirubin ≤1.5 ×ULN , serum transaminase≤2.5×ULN ) ; Pregnant lactate woman ; History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix ; Prior chemotherapy regimen include taxane ( docetaxel paclitaxel ) ; Uncontrolled hypertension ; Intercurrence one following : coronary artery disease , arrhythmia heart failure ; Urine protein &gt; grade 1 ; Any factor influence usage oral administration ; patient clear tendency gastrointestinal bleeding ; Abnormal coagulation function ( INR≥1.5 , APTT≥1.5 ULN ) ; Abuse alcohol drug ; Less 4 week last clinical trial ; Prior treatment antivascular endothelial growth factor anti angiogenesis therapy ; Evidence central nervous system ( CNS ) metastasis ; Disability serious uncontrolled intercurrence infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gastric Carcinoma</keyword>
	<keyword>apatinib</keyword>
</DOC>